1. Home
  2. ZCMD vs CGTX Comparison

ZCMD vs CGTX Comparison

Compare ZCMD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

N/A

Current Price

$0.89

Market Cap

2.0M

Sector

Real Estate

ML Signal

N/A

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$0.99

Market Cap

79.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZCMD
CGTX
Founded
2012
2007
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
79.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
ZCMD
CGTX
Price
$0.89
$0.99
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
1.5M
394.7K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.55
52 Week High
$11.96
$2.26

Technical Indicators

Market Signals
Indicator
ZCMD
CGTX
Relative Strength Index (RSI) 45.33 46.19
Support Level $0.71 $0.93
Resistance Level $0.97 $1.18
Average True Range (ATR) 0.09 0.05
MACD 0.01 -0.00
Stochastic Oscillator 45.26 43.03

Price Performance

Historical Comparison
ZCMD
CGTX

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: